NSCLC remains the leading cause of cancer-related mortality worldwide, with EGFR mutations being a critical driver in approximately 10-15% of lung adenocarcinomas in Western populations, and up to 40% ...
4don MSN
Johnson & Johnson's New FDA Approval Lets Lung Cancer Patients Switch To Monthly Dosing Sooner
The U.S. Food and Drug Administration (FDA) on Tuesday approved a new, simplified monthly dosing schedule for Johnson & Johnson’s JNJ Rybrevant Faspro (amivantamab and hyaluronidase-lpuj). When ...
Johnson & Johnson (NYSE: JNJ) today announced the U.S. Food and Drug Administration (FDA) has approved a new, simplified monthly dosing schedule* for RYBREVANT FASPRO™ (amivantamab and ...
Patients with stage 4 lung cancer and EGFR mutations may benefit from combination therapies that improve disease control. The American Society of Clinical Oncology (ASCO) released updated treatment ...
The FDA has approved Rybrevant Faspro (amivantamab and hyaluronidase-lpuj) as the first and only subcutaneous, chemo-free ...
J INTS BIO, Inc. announced that research findings on its investigational fourth-generation EGFR tyrosine kinase inhibitor ...
Adding the VEGF inhibitor ramucirumab (Cyramza) to the EGFR inhibitor osimertinib (Tagrisso) slowed progression of untreated EGFR-positive non-small cell lung cancer (NSCLC) by 9 months compared with ...
EGFR tyrosine kinase inhibitors (TKIs) are effective treatments for EGFR-mutant non-small cell lung cancer (NSCLC). However, even after undergoing systemic therapy, patients may have oligometastatic ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results